Retinfanlimab
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Retinfanlimab, covering 2026-03-27 to 2026-03-27. Get the full timeline:
Most recent: Clinical Trial Update: Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck [Phase 2]